Nitrosamine risk evaluation: Switzerland follows EU deadline extension
On 9 November 2020, Swissmedic announced to further extend the deadline for the completion of a risk evaluation for medicinal products for human use with a risk of nitrosamine formation or (cross)contamination to 31 March 2021. For biological medicinal products, the final date for the completion of an evaluation is 1 July 2020. Switzerland is thus following the EU, which announced an extension of the deadline in early October.
Due to the COVID-19 crisis a majority of affected companies did not manage to complete the required risk evaluation (step 1 risk evaluation) as of 1 October 2020, the specified deadline. Those companies will now have more time to review their manufacturing processes and carry out the required risk evaluation. The deadlines for steps 2 and 3 (confirmatory tests and changes to the marketing authorization) currently remain unchanged: October 1, 2022 for synthetics and July 1, 2023 for biologicals.
In difference to the EU, Switzerland does not require
- a submission of any documentation once the risk evaluation has been completed. However, the evaluation must be available in the course of inspections.
- any general risk assessments for biologicals, but investigations will be called for when there are identifiable risk factors.
Source:
Swissmedic: News and Updates
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
